Anti-RNase L – Purified in vivo GOLD™ Functional Grade

Based on the provided search results, the clone 2E9 mentioned in the context of in vivo mouse studies is not directly linked to such use. However, I can provide information on how monoclonal antibodies like clone 2E9 are generally used in mouse studies and offer some insights into potential applications.

General Use of Monoclonal Antibodies in Mouse Studies

1. Specificity and Targeting: Monoclonal antibodies are highly specific to their targets, which can be proteins, receptors, or other cellular components. In the case of clone 2E9, there are two distinct uses:

   • RNase L Detection: Clone 2E9 is used to detect 2-5A-dependent ribonuclease (RNase L) .
   • SLA Class II DR Antibody: Although not directly applicable to mouse studies, another clone with a similar name (2E9/13) is used for detecting porcine SLA Class II DR molecules .

2. In Vivo Application: In mouse studies, monoclonal antibodies are often used to:

   • Block Specific Pathways: By binding to specific receptors or molecules, these antibodies can block or modulate immune responses.
   • Deliver Therapeutic Effects: They can also be used to deliver therapeutic effects, such as targeting cancer cells or enhancing immune responses.

3. Dosing and Administration: The dosing for monoclonal antibodies in mouse studies typically ranges from 100 to 250 ?g per mouse, depending on the target and the specific application . Intraperitoneal injection is a common route of administration.

Potential Use of Clone 2E9 in Mouse Studies

While the specific clone 2E9 (targeting RNase L) is not mentioned in mouse studies, if it were used, it could potentially be employed in research related to interferon responses or viral infections, where RNase L plays a critical role. However, detailed information on its use in mouse models is not available in the provided search results.

In summary, while clone 2E9 is not directly linked to in vivo mouse studies in the search results, monoclonal antibodies like it are crucial tools in mouse research, offering specificity and therapeutic potential.

The correct storage temperature for sterile packaged clone 2E9 monoclonal antibodies is ?20?°C.

This recommendation is consistent across reputable suppliers for various monoclonal antibodies of clone 2E9. Storage at ?20?°C preserves antibody integrity for long-term use, especially when the antibody is supplied in a buffer containing stabilizers such as glycerol and BSA. Aliquoting is strongly advised to avoid repeated freeze-thaw cycles, which can degrade antibody activity.

For shorter-term storage (up to a few weeks), refrigeration at 2–8°C or 4°C is occasionally acceptable, but not optimal for long-term preservation. Always consult the specific product datasheet to confirm if your antibody preparation contains protective agents like glycerol or other preservatives, which support storage at ?20?°C without loss of activity.

Key points:

• Long-term storage: ?20?°C (preferably in aliquots; avoid frost-free freezers).
• Short-term storage (if necessary): 2–8°C, only if usage is imminent.
• Room temperature: Not recommended for extended periods; limited to brief transit or use.

If you have the specific formulation (buffer composition) for your sterile packaged clone 2E9, match it against these general recommendations. For most commercial preparations of clone 2E9, ?20°C is the standard.

Commonly used antibodies or proteins with 2E9 in the literature depend on the target; 2E9 is a clone name used for antibodies against distinct proteins, including EGFR and Tau. In the context of Tau antibody 2E9, other commonly used antibodies include those targeting neuronal markers such as alpha Internexin and nuclear stains like DAPI. For EGFR antibody 2E9, researchers often use isotype controls and secondary antibodies for flow cytometry and immunofluorescence, such as Alexa Fluor® 488 goat anti-mouse IgG, mouse IgG1 [ICIGG1], and additional markers like WGA for plasma membranes and DAPI for nuclei.

Supporting details:

• When using the Tau 2E9 antibody, a typical combination is:
  • Chicken antibody to alpha Internexin (NBP1-05208) for cytoskeletal intermediate filaments (red channel)
  • DAPI for nuclear staining (blue channel)
• With the EGFR 2E9 antibody:
  • Secondary antibodies such as Alexa Fluor® 488 goat anti-mouse IgG (H&L) for detection (green channel)
  • Mouse IgG1 [ICIGG1] as the isotype control (used to check specificity)
  • Alexa Fluor® 594 WGA for plasma membrane counterstaining (red channel)
  • DAPI for nuclear counterstaining (blue channel)

Additional relevant information:

• In studies on Tau, researchers frequently use panels of Tau antibodies (such as SP70, Tau-12, Tau-13, Tau-5), often in parallel with 2E9 to distinguish total, phospho-, or isoform-specific Tau, and analyze their specificity and sensitivity for detecting endogenous levels in various cell types.
• For co-staining or multiplexing, antibodies targeting cell-type markers (e.g., neuronal, glial, or synaptic proteins) and post-translational modifications (e.g., phospho-Tau antibodies) are often used alongside 2E9, especially in neurobiology or pathology studies.

Summary:
Frequently used partner antibodies/proteins with 2E9 include lineage markers (alpha Internexin), nuclear stains (DAPI), secondary antibodies (Alexa Fluor conjugates), and isotype controls, with additional marker or epitope-specific antibodies deployed as dictated by experimental context.

Clone 2E9 has been featured in scientific literature across different research contexts, with key findings demonstrating its effectiveness as both a therapeutic antibody and a research tool for protein detection.

TDP-43 Protein Detection and Characterization

Clone 2E9 showed exceptional performance in detecting phosphorylated TDP-43 protein, particularly at the pS409/410 sites. In comprehensive screening studies involving 2,688 B-cell clones, 2E9 consistently demonstrated high immunoreactivity across multiple assay platforms. The clone exhibited stronger immunoactivity to GFP-TDP-25 compared to other tested clones like 23H11 and 23A8, making it a superior choice for research applications.

Immunohistochemistry applications proved particularly successful, with 2E9 effectively detecting cytoplasmic TDP-43 in FTLD-TDP patient brain tissue samples. This capability is crucial since TDP-43 inclusions represent pathological hallmarks of frontotemporal dementia and amyotrophic lateral sclerosis. Based on its superior performance in dot blot, immunoblot, and immunohistochemistry analyses, 2E9 was selected as one of only three promising clones out of thousands screened for generating rabbit monoclonal antibodies.

Tuberculosis Treatment Research

In a completely different therapeutic context, clone 2E9 was developed as a human IgA1 monoclonal antibody targeting mycobacterial ?-crystallin antigen for tuberculosis treatment. This antibody demonstrated high binding affinities for both the mycobacterial target and the human Fc?RI (CD89) IgA receptor.

Protective efficacy was demonstrated in mouse models, where intranasal administration of 2E9IgA1 combined with recombinant interferon-? significantly inhibited pulmonary H37Rv infection. The treatment reduced lung colony-forming units from 4.67 × 10^5^ CFU in controls to 4.33 × 10^4^ CFU in treated mice. Importantly, this protection was only observed in mice transgenic for human CD89, confirming that binding to the CD89 receptor was necessary for the antibody's protective effect.

Clinical Translation Potential

The 2E9 clone represented a "dominant" VH/V? combination with identical variable heavy and kappa light chain sequences to four other clones targeting the same antigen. Human blood culture studies showed that 2E9IgA1 could inhibit tuberculosis infection, though effectiveness varied among different blood donors. The antibody showed synergistic effects with human interferon-? in purified monocyte cultures, supporting its potential for passive immunotherapy development.

These findings across both neurodegenerative disease research and infectious disease treatment demonstrate clone 2E9's versatility and effectiveness as both a diagnostic tool and therapeutic agent, highlighting the importance of thorough antibody characterization workflows in developing clinically relevant applications.